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ABSTRACT 
Sutures have been at the forefront of surgical medicine throughout time. With recent advances 
in suture technology, it has been possible to incorporate biologically active substances to enhance 
suture function and capability. Bioactive sutures represent a modality interest in controlled drug 
and cell delivery to traumatic sites. In this article, a comprehensive literature search of key 
bibliographic databases focusing on suture material fabrication and advanced modification was 
performed. The history, manufacturing process and cost-effectiveness of bioactive sutures are 
presented. Several novel modifications to enhance function in drug and growth factor delivery 
and cell therapy are also reviewed. Different antimicrobial drugs and anaesthetics have been 
shown to be effective in reducing inflammation and bacterial infection. Cellular therapy 
represents a unique modality augmenting the surgical repair of various soft tissue injuries. We 
propose a definition of bio-active sutures as biomaterials that are engineered to have controlled 
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tissue interaction to optimise wound/defect healing, in addition to their essential function in 
tissue approximation. 
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1. INTRODUCTION 
 
A suture is a strand of material used to 
approximate tissue or ligate blood vessels. 
Ligatures, often synonymous with sutures, are 
the same strands of material used to tie ends of 
structures to stop leakage, for example a blood 
vessels [1]. Sutures are generally categorized 
by a combination of their absorption, their 
fibre construct, or their origin as shown in 
Table 1. With ever-changing technology and a 
better understanding of cellular science, it is 
inevitable that suture technology will be 
enhanced to provide better quality and 
outcomes. Strength, different degrees of 
absorption, sterility, and high knot security, 
lack of allergic reaction together with ease of 
handling are among the important properties of 
an ideal suture material [1-3].  
This article will give an in depth focus on the 
current trends in modifying suture materials to 
make them biologically active, and highlight 
novel studies that explore new possibilities.  
 
Categorization Types 
Based on Absorption  Absorbable. 
 Non Absorbable 
Based on Fibre construct  Monofilament 
 Multifilament/Twisted/Braided 
Based on Origin   Synthetic 
 Natural 
Table 1. General categorizations of different suture thread materials.  
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2. BIOACTIVE SUTURES 
APPLICATION 
Several applications of suture modifications 
have been reported. In the following section, a 
review of the different trials is discussed. 
Summary of reported trials is found in Table 2. 
 
2.1. BIOACTIVE SUTURES IN DRUG 
DELIVERY 
Commonly used biomaterials in sutures are 
recognised as foreign materials within the 
body, and often trigger a host of immune 
response. These processes can increase the 
chances of a surgical site infection (SSI) [4]. 
Additionally, the suture itself can be a vessel 
for bacterial colonisation that can result in an 
SSI [5].  
The use of bioactive sutures coated with 
antimicrobial drugs and anaesthetics have been 
shown to be effective in reducing inflammation 
and bacterial infection in the wound site [6, 7]. 
The first commercially available antimicrobial 
suture was a polyglactin suture loaded with 
triclosan (Vicryl Plus®) in 2002 [8]. The initial 
method of drug delivery was to coat the suture 
with a second biodegradable layer but there 
was limited control over the rate of drug 
release, which is a critical factor for optimised 
wound healing [9]. Electro-spinning technique 
was implemented as an alternative pathway 
creating nano-fibrous hybrid poly(ε-
caprolactone) (PCL) suture material with 
controllable drug release. Further assessment 
showed better drug release profile but with 
inferior mechanical properties of developed 
suture [10]. It is important to note that  
although favourable drug release fashion can be 
attained, it should not come at the expense of 
tensile strength contracting the sole purpose of 
using sutures for tissue approximation.  
New methods have been developed to further 
aid controlled drug release while maintaining 
tensile strength. Hu et al. described coaxial 
spinning techniques in which cefotaxime 
sodium (CFX-Na) was mixed with poly(L-
lactic acid) “PLLA” [11-13]. Traditional 
electro-spinning extrudes the CFX-Na/PLLA 
solution directly, while in co-axial fabrication, 
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each fibre has a core and sheath with varying 
concentrations of the drug that were extruded 
together [12, 13]. The concentration of CFX-Na 
was 33% in the core-shell co-axial method and 
3% in the traditional blend-fibres. The higher 
concentration in the co-axial method was 
consistent with a release profile of 14.7% in the 
first 4 h, compared to 24% was released from 
the blend sutures within same period. 
Furthermore, 24-hours assessment of blend 
sutures showed that 40.9% of the total drug was 
released, whereas 20.4% from the core–sheath 
sutures. This was attributed to be a necessity to 
prevent the initial proliferation of bacteria 
directly after the suturing was complete. The 
porosity was also controlled using 
electrospinning as the pores have to be small 
enough so that pathogens are not able to 
penetrate the suture and compromise its 
mechanical integrity, while allowing for a high 
specific surface area to volume ratio to aid bio-
absorbability and effective drug release [14]. 
Hu et al. also reported that the co-axial nano-
fibre surfaces were smoother with fewer defects 
when compared to the blend fibres. The co-
axial fibres also had a better mechanical 
performance with a breaking force of 7.74 ± 
1.66 N, and tensile strength of 80.52 ± 9.31 
MPa for core–sheath sutures than blend sutures 
having 7.14 ± 1.35 N breaking force and a 
tensile strength of 78.64 ± 8.53 MPa [11]. 
Kim et al. also described the blend 
electrospinning of cefotaxime with a 
poly(lactide-co-glycolide) (PLGA) suture 
which eluted 60% of CFX-Na within the first 
24 hours, which represents a high rate of 
release compared to the CFX-Na/PLLA blend 
which released 41% of the drug in the same 
time frame [11, 15]. The difference can at least 
partially be attributed to the slower hydrolytic 
degradation of PLLA due to its semi-crystalline 
condensed structure [16]. 
Additional reports have investigated the use 
of synthetic polymer blends with anti-
inflammatory and anaesthesia drugs. Further 
approaches to control the rate of drug release 
were also investigated, like the incorporation of 
magnesium and aluminium hydroxycarbonates 
(HT) compounds into suture material. These 
HT compounds consist of a layer of inorganic 
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clays that self-arranges to form a bi-layer and 
becomes a nano- or micro-vessel for 
immobilising anionic drugs with more 
sustainable drug release [10, 17].  
A melt-spun suture containing poly(ε-
caprolactone)  (PCL) and diclofenac (Dic), as 
an antiinflammatory drug, created by forcing a 
polymer melt through a small spinneret 
capillary to obtain strong fibres (11).  In-vivo 
assessment showed a reduction in the 
inflammatory profile.  
Catanzano et al. also conducted an in-vitro 
release study of PCL/HT-Dic in Phosphate 
buffered saline (PBS) at pH 7.4 and 37
o
C.  The 
PCL/HT-Dic conjugate showed controlled 
release over 55 days suggesting that the release 
profile can be finely tuned. There was a 
significant reduction in tensile strength as the 
breaking stress was 400 MPa for the PCL 
control, but approximately 190 MPa for the 
PCL/HT-Dic [10]. Knotting did not have a 
significant effect on tensile strength. 
Another example of a controlled release 
system was presented by Weldon et al. Sutures 
were fabricated using poly-(lactic co-glycolic 
acid) (PLGA) mixed with bupivacaine HCl and 
extruded to form a blend fibre. It was noted that 
the suture exhibited a controlled and consistent 
release profile at the expense of tensile 
strength. The hybrid fibres showed a three-fold 
decrease with respect to pure PCL fibres in 
terms of breaking stress.  The tensile breaking 
stress force was < 1.5 N for 6-0, 4-0 and 2-0 
sizes (specific American Pharmacopoeia 
Standards [18])   Poly(lactic-co-glycolic acid) 
(PLGA, 90:10 glycolide:L-lactide) sutures 
loaded with bupivacaine  at more than 15 wt.% 
of the suture material  demonstrated  a 88% 
reduction in tensile strength compared to 
control [18].  
2.2. BIOACTIVE SUTURE IN 
GROWTH FACTOR DELIVERY 
Different bio-active molecules including 
peptides and hormones influence cell division, 
growth, differentiation and protein synthesis. 
Growth factors were being used to aid healing 
in tissues with variable level of success [19]. 
The progress on incorporation of the different 
growth factors with bio-active suture 
fabrication aiming to alter the healing 
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properties of approximated tissue is 
summarised as follows. 
Kopf et al. reported the use of vascular 
endothelial growth factor (VEGF)-poly(D,L–
Lactide) (PDLLA)  blend coated  on non-
absorbable polyethylene terephthalate polyester 
(PET) sutures (Ethibond) to treat meniscal 
lesions. This was later concluded in that; it did 
not improve meniscal healing or increase 
angiogenesis in sheep meniscal model [20]. 
However, Bigalke et al developed an effective 
VEGF/ poly(L-lactide) (PLLA) blend coated 
polydioxanone (PDS) suture with improved 
mechanical properties compared to uncoated 
ones and  a greater concentration (2 µg/100 mm 
PDS suture) than did Kopf reported (0.1 µg/100 
mm PET suture). Bigalke et al. showed 
increased biological activity and cellular 
viability using human umbilical vein 
endothelial cells.  Further in-vivo assessment 
using rat hind limb model showed significant 
histologically enhanced vascularisation in the 
wound site sutured with PLLA/1.0 μg VEGF-
coated suture material [21]. The disparity in 
results in terms of disruption of the coating 
layer during suture entry through tissue may be 
explained by the concentration of growth 
factor, coating process, and polymer structure.  
  
Recombinant human platelet-derived growth 
factor BB (rhPDGF-BB) [22, 23] and growth 
factor 5 (GDF5) were also investigated [19, 24, 
25]. Cummings et al. used rhPDGF-BB coated 
Vicryl® (Ethicon, Somerville, NJ) a 
multifilament absorbable sutures made of poly 
(lactide-co-glycolide) fibres to repair transacted 
Achilles tendon in mice model and showed a 
marked increase in tendon tensile strength [22]. 
Dines et al. showed through in-vivo assessment 
showed that GDF5 was beneficial for up to 
three weeks after the sutures were 
administered, resulting in higher tensile load 
and stiffness compared to the control group in 
the initial healing period (p=<0.05) [26]. Henn 
et al. also presented similar results through an 
in-vivo trial using gelatin/GDF5 coated 
Vicryl® polyglactin 910 sutures on zone II 
flexor tendon repair [25].  
The use of growth factors in bioactive sutures 
has shown a largely dose dependent 
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relationship between the active substances and 
biological activity as shown, however it is not 
known whether this is due to the inherent 
nature of the growth factors or due to the 
absence of an appropriate controlled release 
system.  
2.3. BIOACTIVE SUTURES IN CELL 
DELIVERY AND TRANSFER 
Cell therapy represents a unique modality 
augmenting the surgical repair of various soft 
tissue injuries. The application of such process 
associated with certain challenges in cell 
hosting and delivery [27, 28]. Bioactive sutures 
played a major role as a vehicle (scaffold) to 
host and deliver various cell lines. In this 
section, a critical review of the currently known 
trials implementing the use of bioactive sutures 
is presented.  
Casado et al. investigated a range of clinically 
used sutures with different surface coatings as a 
carrier of mesenchymal stem cells (MSCs). 
They showed that Vicryl ® (copolymer of 90% 
glycolide and 10% L-lactide, PLGA) was 
superior in its cell attachment properties than 
Dexon-II ® (braided absorbable suture made of 
polyglycolic acid (PGA) and coated with 
copolymer of poly(-caprolactone/glycolide ), 
Assufil® (braided multifilament absorbable 
suture made of PGA  and coated with a mixture 
of polycaprolactone and calcium stearate), Safil 
Quick® (braided absorbable suture made of 
PGA and coated with magnesium stearate),  
Safil® (braided absorbable suture made of 
PGA and coated with hydrolytic degradable 
glyconate) and Ticron® (non-absorbable suture 
made of polyethylene terephthalate coated with 
silicone). Vicryl was then coated with porcine-
derived gelatin, poly-L-lysine hydrobromide, or 
treated with NaOH. Porcine and murine bone 
marrow-derived mesenchymal stem cells 
(BMSCs) were used in their assessment. NaOH 
treatment and poly-L-Lysine coating associated 
with statistically significant highest level of cell 
attachment. In terms of cell adhesion tendency, 
poly-L-Lysine coated sutures were highest in 
their adhered cells (P=0.053). Mechanical 
assessment however, showed reduction of the 
tensile strength with NaOH treatment with no 
significant difference in the in-vitro 
degradation rate [29]. The results presented 
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reflect the importance of how the modification 
of material structure and properties of sutures 
can increase the surface area with an altered 
porosity and more hydrophilic interference. 
However, a trade-off of reduction of 
mechanical compliance/strength could make 
such treatment of less clinical importance. 
Vicryl was also coated differently using 
fibronectin, poly-L-lysine or albumin in order 
to increase its cell attachment. The coating was 
applied through freeze-drying technique. In-
vitro and in-vivo assessments performed by 
using both human bone marrow stromal cells 
(BMSCs) and rat mesenchymal stem cells 
(MSCs). Albumin coating was associated with 
significantly higher human BMSCs attachment 
with higher proliferation rate compared to other 
coated sutures and uncoated controls. The 
sutures were then fixed to rat’s triceps surae 
muscle where viable cells were seen up to 5 
week's post-implantation [30]. In a follow-up 
study, the authors further investigated the 
potential mechanical effects after incubating 
such absorbable sutures. They concluded that a 
non-significant difference exists in breaking 
force between 48hrs incubated and control 
sutures. A significant reduction however was 
found in the breaking force by 16 to 19% after 
incubating the sutures for a longer period (168 
hours) [31].  
Tendon injuries represent a challenging 
obstacle in which suturing repair is the gold 
standard treatment. This however is associated 
with certain limitation in which histological 
assessment of repaired tendon showed a distinct 
acellular zone surrounding the repairing sutures 
with a negative effect on the healing tendon 
[32]. Augmentation of the repair process with 
cell-loaded sutures was tried. 
FiberWire ®, sutures are made with a core of 
non-absorbable polyethylene and coated with a 
braided polyester for lower friction and cell 
adhesion. This suture material is characterized 
by high mechanical properties as a promising 
choice in tendon repair. The maximum load to 
failure reaches up to 620 ± 29 N, stiffness up to 
62 ± 18 N/mm, and a strain of 23 ± 7% [33]. 
Fiberwire ® suture was coated with fibronectin, 
poly-L-lysine, or phosphate-buffered saline 
(PBS). In-vitro assessment using mouse 
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C3H10T1/2 pluripotent embryonic stem cells 
(ESCs) showed a significant adherence with 
both types of coating compared to PBS 
controls. Poly-L-lysine was however superior 
in its attachment properties [34]. This study 
showed the possibility to activate Fiberwire 
sutures by increasing its surface attachment 
properties; however it lacked further detailed 
assessment of cellular activity and adherence 
properties at in-vivo environment. In a 
subsequent study, the authors have utilized the 
same coating technique using only poly-L-
lysine in an in-vitro assessment of ESCs 
survivability. Decellularised rabbit Achilles 
tendons were used as a model in which cell-
seeded coated sutures were passed through 
adjacent tendon segments. They showed 
successful delivery of cells with preserved 
activity and proliferation properties after 48 and 
96 hours of incubation (P<0.001) even after 
tissue passing effect [35].  
Yao et al. investigated the use of Ethibond 
Excel ® suture in cell delivery [36]. Ethibond 
Excel ® made from braided polyester (PET) 
with polybutyrate coating that is not 
absorbable. The mechanical properties of these 
sutures were shown to reach up to 247 ± 10 N 
as a maximum load.  Stiffness reached up to 25 
± 2 N/mm, and strain up to 18 ± 2 % [33]. 
Coating the sutures with poly-L-lysin and 
intercellular cell adhesion molecule 1 (ICAM-
1) was done. Fluorescent-labelled rat MSCs 
were used for suture seeding. In-vivo 
assessment with rat’s Achilles tendon repair 
was investigated and showed a significantly 
increased load to failure level in repaired 
tendon with cell-seeded sutures compared to 
controls at both 7 and 10 days. Additional 
improvement in the mechanical properties 
tested  up to 28 days post repair  was not 
statistically significant [36].  
Collagen was also used as a coating molecule 
to increase cell attachment properties. Type I 
bovine collagen was used to coat sutures made 
of a non-absorbable polyethylene/polyester 
(Arthrex, Naples, FL). The coating was applied 
by overnight incubation of either native or 
denatured (heat treated) collagen at a 
concentration of 0.5 mg/ml followed by air-
drying. Human osteoblasts (HoBs) and 
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tenocytes were both used in the in-vitro 
adhesion assessment. Adhesion assay of HoBs 
and tenocytes showed no significant difference 
between collagen-coated and uncoated sutures. 
Proliferation assay however showed 1.9 and 1.8 
fold increases in proliferation of HoBs and 
tenocytes, respectively when denatured 
collagen coating is used compared to native 
collagen. The effect of the knot tying process, 
sterilization technique, shelf life availability, 
and mechanical properties were also tested. It 
was shown that HoBs adhesion had a 1.9 fold 
increased amount when denatured collagen 
knotted suture is used compared to uncoated 
control. Tenocytes showed a 2.1 fold increased 
adhesion when denatured, or native collagen 
knotted suture is used compared to control. No 
significant difference revealed when freshly 
applied coating compared to 6-week post-
coating indicating the possible availability of a 
shelf product. No significant difference was 
also found in terms of cell adhesion or 
proliferation between Ultraviolet or ethylene 
oxide sterilization of denatured collagen-coated 
sutures [37].     
Different protocols utilizing other activation 
molecules like RGD (Arginine-glycine-aspartic 
acid) peptides were also tried. RGD is an amino 
acid sequence presents in different extracellular 
matrix proteins with various effects that involve 
cell attachment and activation. RGD was 
attached to silk suture. The attachment process 
was obtained through covalent coupling by 
activating the carboxyl group of GRGDS 
peptides (glycine-arginine-glycine–aspartic 
acid-serine). Human derived tenocytes were 
used in the in-vitro assessment model. They 
showed significantly more human tenocytes 
attachment at 4 hours of seeding on RGD-silk 
surface. By six weeks of culture, the cells 
assumed the best morphologic features on silk-
RGD coated surfaces compared to silk alone 
and tissue culture plastic control. Growth and 
proliferation were also significantly higher in 
silk-RGD sutures than other groups [38]. 
Additional report investigated RGD with the 
use of high-strength non-absorbable 
polyester/polyethylene (PE/PEE) using acid 
hydrolysis. They showed significantly higher 
cell attachment together with a possibility of a 
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shelf product. The modified suture was also 
shown to withstand sterilization with both 
ultraviolet light and ethanol immersion with no 
significant effect on load to failure strength 
[39].  
Pascual et al. have investigated the potential 
of direct attachment of fluorescent-labelled 
adipose-derived stem cells (ADSCs) to Vicryl 
® sutures. The attachment process obtained 
through direct incubation of the cells with 
sutures in ultra-low attachment culture plates.  
In-vivo assessments using rat’s colonic 
anastomosis repair showed that a significant 
difference in the adhesion index with Vicryl-
ADSCs sutures compared to cell free sutures 
[40]. In another report, the authors investigated 
these sutures with icodextrix 4% intra-
peritoneal injection to decrease adhesion 
formation in syngeneic BDIX rats and showed 
increased anastomosis resistance with a similar 
adhesion index to conventional sutures [41]. 
Vicryl-ADSCs sutures were also investigated in 
modulating the inflammatory response in rat’s 
tracheal resection repair [42]. Histological 
assessment showed abundant macrophages with 
low neutrophil count with viable ADSCs at day 
1 and 4 post tracheal tissue in approximation 
with cell-loaded sutures. The authors 
mentioned another preliminary assessment of 
the sutures in which cell density reduced after 
being passed twice in muscle tissue with no 
detailed description of the cell adhesion 
tendency. 
 
2.4. GENERAL SUTURE 
FABRICATION TECHNIQUES 
IMPLEMENTING ACTIVE MOLECULE 
INCORPORATION 
Modification of commonly available suture 
materials with the addition of different 
substances aiming to alter certain mechanical 
and surface properties or more importantly, 
with the addition of an active molecules 
altering certain physiologic phenomena were 
investigated and summarised in the following 
section.  
Bioglass® was one of the material used to 
modify sutures. . 45S5 Bioglass® is a bioactive 
material that contains 45% SiO2, 24.5% Na2O, 
24.5% CaO, and 6% P2O5. This material was 
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implemented for its osteo-conductive and 
osteo-productive behaviour due to a layer of 
hydroxyapatite formation upon contact with 
biologic fluids. This material was used to coat 
Vicryl® sutures in order to alter its extent of 
degradation using layer pressing technique. An 
initial reduction in the tensile strength of 
treated sutures (404 MPa Vs. 463 MPa in 
control) was found and was attributed to the 
manufacturing technique implemented [43]. In 
order to avoid the harmful pressing effect upon 
incorporation of  Bioglass® to the sutures, the 
authors reported a  slurry-dipping technique. It 
was shown that homogeneous coating with 
higher chemical properties represented by 
hydroxyapatite formation was obtained. 
However, mechanical assessment showed also 
a lower tensile strength of modified sutures 
compared to the native one (385 MPa vs. 467 
MPa). Concerning the tensile strength assessed 
after 28 days of SBF incubation, the coated 
suture showed 83 MPa compared to 88 MPa for 
uncoated ones [44].  
Silver ion (Ag
+)
 is known for its antimicrobial 
properties. Blaker et al. investigated the use of 
Ag
+
 containing bioglass as a coating molecule 
of suture material. Vicryl® and Mersilk® were 
used in the assessment process. Mersilk® is a 
braided non-absorbable suture that is made of 
silk and beeswax coating. A sol-gel derived 
silver-doped bioactive glass (AgBG) powder 
was used. They showed that with the use of 
powder with < 38 μm particle size and an 
immersion time of 2 minutes for Vicryl and 5 
minutes for Mersilk suture, a uniform, stable 
coating was obtained. Knot tying or passing 
through eyes of surgical needle had no effect on 
coating process. The authors showed that the 
addition of Ag
+
 did not affect the biologic 
behaviour of bioactive glass by hydroxyapatite 
formation. However, the incorporation of Ag
+
 
was not clearly assessed [45].  
Subsequent reports investigated the 
antibacterial properties using silver coating. 
Mersilk sutures coated with AgBG in a similar 
fashion described earlier. Incubation of AgBG 
coated suture, Bioglass 45S5 coated sutures and 
uncoated mersilk sutures with Staphylococcus 
epidermis at both batch and flow cell 
techniques was made. AgBG coating associated 
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with a statistically significant lower colony 
forming units (CFUs) with limited cell 
attachment in comparison to other groups [46]. 
However, assessment of silver ion release 
assays together with silver ion quantification,  
period and interval length of release were 
lacking. 
De Simone et al. investigated the use of in-
situ photo-reduction of silver solution 
containing the suture material using ultraviolet 
(UV) light. The solution was made containing 
0.5 wt/v% silver nitrate mixed with 5 v/v% 
methanol in which the later was added as a 
reducing factor. Photo-reduction resulted in the 
deposition of silver clusters on silk sutures 
used. The use of this modality was associated 
with uniform distribution of silver particles on 
the surface of the sutures as evident by electron 
microscopic assessment. No significant 
reduction in the tensile strength of the treated 
sutures was found. Anti-bacterial assessments 
using E.coli and Staphylococcus aureus 
incubation showed reduced growth tendency 
with reported percentage of antibacterial 
efficacy to be 78% against E.coli and 81% 
against Staph. Aureus. Silver treatment sutures. 
Cell cytotoxic analysis of fibroblasts incubation 
with treated sutures resulted in 82% cell 
viability compared to 92% with untreated 
sutures [47]. Although the reported findings are 
of interest, detailed statistical analysis needs 
further elaboration.  
An additional report investigated the use of 
silver nanoparticles to coat Vicryl® sutures. In 
this study, the silver coating was obtained 
through layer-by-layer deposition. The silver 
solution was prepared by mixing silver nitrate 
with poly-methacrylic acid under ultraviolet 
light to yield silver nano-particles (AgNPs) 
after photo-reduction. Analysis of modified 
sutures showed denser deposition of silver 
particles depending on the cycles of 
immobilization. In-vitro antibacterial activity 
against E.coli showed a significant growth 
inhibition area around the silver-coated and 
antibacterial (Vicryl Plus) sutures compared to 
control. Extended inhibition (9 days) was 
significantly higher in silver-coated sutures 
compared to other groups. In-vivo assessment 
with the use of mouse intestinal anastomosis 
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repair showed reduction in the inflammatory 
response with less early neutrophil and  
macrophage infiltrates compared to controls. 
Additionally anastomosis sites treated with 
silver coated sutures showed more collagen 
content [48].  
Other substances like butyric acid (BA) have 
been incorporated into suture materials. BA is a 
naturally formed fatty acid with a potential 
effect on angiogenesis. Several reports had 
investigated its incorporation in tendon and 
ligament suture repair. Soaking Ticron® 
sutures (ultra-high- molecular weight 
polyethylene) with BA at a concentration of 6.2 
μg/cm in meniscal repair resulted in significant 
mechanically superior repair strength in 
comparison to uncoated controls [49]. 
Additional effort reported the use of same 
sutures in tendon repair with significantly 
increased tensile strength and young's modulus. 
The attributed results linked to higher 
angiogenesis and cell proliferation [50, 51].  
Doxycycline was also used in such 
assessment. Doxycycline was linked with 
modulation of the inflammatory process 
through inhibiting matrix metalloproteinase 
(MMPs) and improving tendon suture repair. 
The coating process was applied using plasma 
treatment of sterile polybutester monofilament 
sutures (Novafil, Switzerland). Incubation with 
fibrinogen assumed cross liking to the suture 
surface. This was followed by doxycycline 
introduction. The authors showed improved 
suture holding capacity and force of failure of 
repaired animal Achilles tendon [52].
 
Application Bio-active Suture Type Remarks 
Drug Delivery 
 
Cefotaxime loaded PLLA suture. 
(Hu, Huang, & Liu, 2010) 
Showed that blend braided fibres retain more rigidity and strength 
compared to non-braided sutures. 
PLGA with bupivacaine. (Weldon et 
al., 2012) 
Electrospun drug-eluting sutures for local anaesthesia. 
Suture offered very low tensile strength 
 
Triclosan-coated polyglactin 910. 
(Okada et al., 2014) 
Anti-microbial coated suture to reduce incidence of SSIs 
Incidence of SSI reduced from 14.5% to 4.5% 
PCL suture with diclofenac and 
hydrotalcite. (Catanzano et al., 2014) 
Sutures containing nanohybrids for local delivery of anti-
inflammatory drugs 
Growth Factor Delivery PDLLA-VEGF. (Kopf et al., 2010) 
 
 
Intended in the treatment of meniscal lesions using VEGF but 
lacked a control release system. 
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PLLA-VEGF. (Bigalke et al., 2014) 
 
 
Intended to promote angiogenesis in sutured gastrocnemius 
muscle tissue using VEGF 
Vicryl ®-rhGDF-5. (Dines et al., n.d., 
2011) 
Intended in tendon repair using rhGDF-5 in which entry trauma 
considered and factored into GF release calculations 
5-0 polyglactin 910 sutures-rhGDF-5 
(Henn et al., 2010) 
 
Intended in tendon repair using rhGDF-5 with significant increase 
in maximum load. 
Vicryl® - rhPDGF-BB (Cummings et 
al., 2012) 
 
Intended in rotator cuff healing using rhPDGF-BB with 
improvement in healing results 4 weeks post repair. 
FiberWire ®-rhPDGF-BB 
(Uggen et al., 2010) 
Gelatin suture coating with intended application in Achilles 
tendon healing using rhPDGF-BB 
Biologically active molecule 
incorporation 
Vicryl-Mersilk®/silver-doped 
bioglass coating. (Blaker et al., 2004) 
 
Intended in the delivery of silver ion for antibacterial properties. 
Silk - Silver coating. (De Simone et al., 
2014) 
Intended in the delivery of silver ion for antibacterial properties 
demonstrated against E.coli and staph. S. aureus. 
 
Vicryl - nano-silver coating. (Zhang et 
al., 2014) 
Intended in the delivery of silver ion for antibacterial properties. 
Ticron butyric acid soaking. (Acton et 
al., 2004, Leek et al., 2012, Tracy et al., 
2011) 
Intended in the delivery of active molecule to promote 
angiogenesis. 
Polybutester monofilament sutures / 
fibrinogen / Doxycycline coating. 
(Pasternak et al., 2007) 
Intended in the delivery of Doxycycline modulating Matrix 
metalloproteinase (MMPs) 
Cell Delivery and Transfer 
 
Vicryl® treatment with NaOH / 
gelatin / poly-L-lysin. (Casado et al., 
2014) 
Intended for MSC cell delivery. 
 
Vicryl® coating with 
Albumin/Fibronectin / Poly-L-lysine. 
(Horvathy et al., 2013a) 
Intended for MSC cell delivery. 
 
Vicryl® coating with albumin/ 
fibronectin / Poly-L-lysine .(Horvathy et 
al., 2013b) 
Intended for MSC cell delivery. 
 
FiberWire® coating with poly-L-
lysine / Fibronectin / PBS. (Yao et al., 
2008) 
Intended for ESC cell delivery. 
 
FiberWire® coating with poly-L-
lysine/ PBS. (Yao et al., 2011) 
Intended for ESC cell delivery. 
 
Ethibond® coating with poly-L-lysine 
/ ICAM-1. (Yao et al., 2012) 
Intended for MSC cell delivery. 
 
Polyethylene/polyester coating with 
native type I collagen / denatured type I 
collagen. (Mazzocca et al., 2007) 
Intended for human osteoblasts and Tenocytes delivery. 
 
Silk suture with RGD coating. 
(Kardestuncer et al., 2006) 
Intended for tenocytes delivery. 
 
Table 2. Summarised literature implicating the use of different biologically active suture 
materials.  
 
3. CONCLUSION. 
As summarised in this article, the scope of 
sutures and their materials have vastly evolved 
since the use of horsehairs and ant heads for 
tissue approximation. With the advent of 
antibiotics, integration of suture material and 
antimicrobial agents have been tried and 
tested. The effect of having bioactive sutures 
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extends to conserving costs on follow-ups and 
potential further treatment post surgical 
procedure. A well devised human experiment 
using triclosan-coated sutures showed a 
savings of at least $4000 per surgical site 
infection prevented for the hospital. In 
addition to cost savings the sutures also 
conveyed an improvement in surgical site 
infection rates [53]. This model can be used to 
infer the potential cost benefits for bioactive 
sutures. As technology takes us to new 
advancements in sutures, the authors propose a 
definition for bioactive sutures that will hold 
true for future prospects. Bioactive sutures are 
“biomaterials that are engineered to have 
controlled tissue interaction to optimise 
wound/defect healing, in addition to their 
essential function in tissue approximation and 
ligation”. 
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